Abstract
There has been a surge in human papillomavirus (HPV)-positive oropharyngeal cancers (OPCs) in the West. Although the prognosis of HPV-positive OPC is good, de-escalation strategies have so far not been able to confirm comparable cancer control. We examine the strategies implemented across the globe to safely reduce toxicities in HPV-positive disease. HPV-negative OPC has a poorer prognosis and is more prevalent in Eastern countries. We outline the intensification strategies currently used in HPV-negative cancers, with an aim to better prognosis. With recent improvements in clinical trial frameworks in Eastern countries such as India, we discuss areas where joint collaborative research between Western and Eastern countries could further improve outcomes in OPC.
Original language | English |
---|---|
Pages (from-to) | 510-519 |
Number of pages | 10 |
Journal | Clinical Oncology |
Volume | 31 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2019 |
Keywords
- East
- HPV
- oropharyngeal cancer
- West
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging